Literature DB >> 35428009

Simultaneous quantification of trimethoprim metabolites in pediatric plasma.

Robert T Tessman1, Whitney Nolte2, Paul Toren3, Kim Gibson4, Linda Vu5, Jennifer Goldman6.   

Abstract

The dual agent antibiotic, trimethoprim/sulfamethoxazole (TMP-SMX), has been prescribed to treat or prevent infections for over 50 years. However, there are no published validated analytical methods for the measurement of TMP metabolites in humans. We developed methodology enabling reliable quantification of TMP and 5 metabolites in human plasma. Chromatographic separation was achieved in less than 8 min using a biphenyl column. Analytes were detected in positive electrospray mode using a tandem Waters Xevo-TQ-XS mass spectrometer. Precision and accuracy values for all analytes were within 15% of nominal values during assay validation.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Idiosyncratic adverse drug reactions; Metabolism; Tandem mass spectrometry; Trimethoprim; Validated methodology

Mesh：

Substances：

Year:  2022        PMID： 35428009      PMCID： PMC9152843          DOI： 10.1016/j.jchromb.2022.123232

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN： 1570-0232            Impact factor:   3.318


  15 in total

Review 1.  Considerations when prescribing trimethoprim-sulfamethoxazole.

Authors:  Joanne M-W Ho; David N Juurlink
Journal:  CMAJ       Date:  2011-10-11       Impact factor: 8.262

2.  Trimethoprim: The overlooked component of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactions.

Authors:  Jennifer L Goldman; Leon van Haandel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-06-04       Impact factor: 2.890

3.  Trimethoprim metabolites in rat, dog and man: qualitative and quantitative studies.

Authors:  D E Schwartz; W Vetter; G Englert
Journal:  Arzneimittelforschung       Date:  1970-12

4.  Antibiotic Drug Use and the Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Population-Based Case-Control Study.

Authors:  Noel Frey; Andreas Bircher; Michael Bodmer; Susan S Jick; Christoph R Meier; Julia Spoendlin
Journal:  J Invest Dermatol       Date:  2017-12-19       Impact factor: 8.551

5.  Urinary biomarkers of trimethoprim bioactivation in vivo following therapeutic dosing in children.

Authors:  Leon van Haandel; Jennifer L Goldman; Robin E Pearce; J Steven Leeder
Journal:  Chem Res Toxicol       Date:  2014-01-13       Impact factor: 3.739

Review 6.  How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction.

Authors:  Tiffany Cho; Jack Uetrecht
Journal:  Chem Res Toxicol       Date:  2016-11-08       Impact factor: 3.739

7.  In Vitro Hepatic Oxidative Biotransformation of Trimethoprim.

Authors:  Jennifer L Goldman; J Steven Leeder; Leon Van Haandel; Robin E Pearce
Journal:  Drug Metab Dispos       Date:  2015-07-02       Impact factor: 3.922

8.  A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity.

Authors:  H Jick; L E Derby
Journal:  Pharmacotherapy       Date:  1995 Jul-Aug       Impact factor: 4.705

9.  Self-reported antibiotic allergy incidence and prevalence: age and sex effects.

Authors:  Eric Macy; T Poon K-Y
Journal:  Am J Med       Date:  2009-08       Impact factor: 4.965

10.  Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation.

Authors:  Dean J Naisbitt; John Farrell; S Fraser Gordon; James L Maggs; Christoph Burkhart; Werner J Pichler; Munir Pirmohamed; B Kevin Park
Journal:  Mol Pharmacol       Date:  2002-09       Impact factor: 4.436
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.